Navigation Links
Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
Date:9/24/2009

d to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
2. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
5. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
6. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
11. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 OriginOil Inc. ... high-speed, chemical-free process to clean up large quantities of ... CEO Riggs Eckelberry reported on the launch of the ... a site provided by partner STW Resources . ... 1000 barrels per day (bpd) and achieved a 99.8% ...
(Date:9/30/2014)... BALTIMORE and ROCKVILLE, Md., Sept. 30, 2014 /PRNewswire/ ... private-public partnership focusing on commercializing market-relevant biohealth innovations and ... Maryland , announced today that venture capitalist, ... as a strategic advisor. Dr. Fernandez will be a ... Gap Fund, which will provide up to $50 million ...
(Date:9/30/2014)... iLab Solutions announced the results of its ... on core facility operations, growth and utilization as well ... In its 4th year running, a number of long-term ... decrease in the percentage of revenue that comes from ... constraints of this trend. When asked, “What are your ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
... Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies ... , , (Logo:   ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... July 29 Omeros Corporation (Nasdaq: OMER ) ... facility under which it may sell up to $40 ... Opportunity, Ltd. (the "investor") over a 24-month period. Omeros is ... enter into and consummate other equity, debt and non-dilutive financing ...
... ,, LONDON , ... pleased,to announce the appointment of Dr Neill Moray Mackenzie ... to CMPT a long record of executive,board level management ... Genetics Ltd, Oxford Biomedica plc (an LSE,listed company), Avidex ...
Cached Biology Technology:BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5
(Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the American Association of Immunologists 2013 ... from July 13-18, 2013. These awards are meant ... scientists from underrepresented groups into the mainstream of ...
... progress in the search for the first broad-spectrum drugs ... common infectious diseases. Their study on these potential drugs ... the journal ACS Medicinal Chemistry Letters . ... HRV infections cause mild disease, they can lead to ...
... teachers to sing melodies accurately, according to a new ... the University of Kaiserslautern in Germany. Their analysis of ... songbirds, brain processes. The work is published online in ... is considered to be one of the most complex ...
Cached Biology News:Songbirds turn on and tune up 2
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Recombinant Mouse Wnt-3a...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: